Omeprazole Ratiopharm

Omeprazole, the active ingredient in Omeprazole Ratiopharm, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Omeprazole Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that lowers gastric acidity across several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief by decreasing esophageal acid exposure. - Peptic ulcer disease: promotes ulcer healing through sustained acid suppression. - Helicobacter pylori eradication regimens: enhances eradication rates when combined with antibiotics. - Zollinger‑Ellison syndrome: controls pathological hypersecretion of gastric acid.

Common Side Effects: - Headache - Abdominal pain - Diarrhoea - Nausea - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis or angioedema - Clostridioides difficile‑associated colitis - Low magnesium levels (hypomagnesemia) with prolonged use - Interstitial nephritis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Elevated liver enzymes or hepatitis

Before initiating therapy, consider the following precautions: - Assess renal function: dose may need adjustment in severe renal impairment. - Monitor magnesium levels: prolonged use can cause hypomagnesemia. - Avoid abrupt discontinuation: may lead to rebound acid hypersecretion. - Use with caution in elderly patients: higher risk of fractures and falls. - Store at room temperature: keep in the original container, protect from moisture and light.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and therapeutic failure. - High‑dose methotrexate: increased toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: may raise serum concentrations. - Diazepam: potential increase in plasma levels.